12 results on '"Koiss R"'
Search Results
2. Repeat conisation or HPV test? What should be done if histology of the primary conisation requires a second conisation?
- Author
-
Koiss, R., Babarczi, E., Jenei, C., Göcze, P., Horányi, D., and Siklós, P.
- Subjects
- *
CERVIX uteri diseases , *DNA , *ELECTROSURGERY , *SURGICAL excision - Abstract
The article presents s retrospective study which investigates the sensitivity of papillomaviruses (HPV) DNA testing towards the reduction of the number of repeat (re)-conisations. The study uses loop electrosurgical excision procedure (LEEP) in 438 cervical conisations. Conclusions show that pre re-conisations HPV testing can be used in the reduction of the number of re-conisations where the high-risk HPV test is either does not confirm or negative to the proven HPV type.
- Published
- 2012
3. Reproducibility of colposcopy quality indicators-A survey among members of the European Federation for Colposcopy.
- Author
-
Randrup TH, Leeson S, Ciavattini A, Eldib A, Grigore M, van Haaften-de Jong AM, Jariene K, Kesic V, Koiss R, Kotaniemi-Talonen L, Quaas J, Raud T, Zodzika J, and Hammer A
- Subjects
- Humans, Female, Europe, Reproducibility of Results, Adult, Surveys and Questionnaires, Middle Aged, Societies, Medical, Early Detection of Cancer standards, Colposcopy standards, Colposcopy statistics & numerical data, Quality Indicators, Health Care, Uterine Cervical Neoplasms diagnosis
- Abstract
Introduction: Colposcopy is an important part of the diagnostic work-up of women with an abnormal cervical screening test as it is used to guide the collection of biopsies. Although quality assurance has been used in the evaluation of screening programs, not much is known about quality indicators for the diagnostics and treatment of screen-positive women. Therefore, the European Federation for Colposcopy developed quality indicators aiming to support colposcopy practice across Europe. We performed a survey of colposcopy cases to determine if the quality indicators are understandable, relevant, and reproducible., Material and Methods: We conducted a survey among all members of the European Federation for Colposcopy Quality and Standards Group from November 2022 to March 2023. Members were asked to collect information on a total of 17 quality indicators for 50 women who had been newly referred for colposcopy due to an abnormal screening test between January 1, 2020 to December 31, 2021. Results were reported descriptively., Results: We included data on 609 cases from 12 members across Europe. The majority of the quality indicators were either achieved or within reach of the agreed standard, often due to few countries with outlying data. One quality indicator had very low performance, although stratified results indicated that two countries had different clinical management of the patient type thereby skewing the results. In addition, discrepancies between the number of cases included in each quality indicator raised concerns regarding potential misunderstanding of the quality indicator and its objective., Conclusions: Quality indicators on colposcopy must be understandable to those collecting data, highlighting the importance of validating quality indicators before data collection., (© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).)
- Published
- 2024
- Full Text
- View/download PDF
4. [Quality and performance indicators of the pilot program for cervical cancer screening by health visitors].
- Author
-
Vajda R, Árváné Egri C, Kovács A, Budai A, Döbrõssy L, Koiss R, Kívés Z, and Boncz I
- Subjects
- Adult, Age Factors, Aged, Female, Humans, Hungary, Middle Aged, Papillomavirus Infections epidemiology, Patient Compliance statistics & numerical data, Pilot Projects, Prevalence, Program Evaluation, Qualitative Research, Quality Indicators, Health Care organization & administration, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Dysplasia epidemiology, Early Detection of Cancer methods, Nurses, Community Health organization & administration, Papillomavirus Infections diagnosis, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Dysplasia diagnosis
- Abstract
The aim of our analysis was the assessment of the qualitative and performance indicators of a pilot program for health visitors' cervical cancer screening. The analysis involved the data from the Communication module of the Office of the National Chief Medical Officer. In the examined period (October, 2013 - September, 2015) the participation indicators of women aged 25-65, the prevalence rates of human papillomavirus and the cervical intraepithelial neoplasia were determined. In the screening period, the call-in rate was 32.45% nationally, with the compliance of 8.26%. The occurrence of a positive result was 1.85% nationally, with the highest rate in Hajdú-Bihar county (7.24%). HPV infection was detected in 113 cases (0.45%) nationally, HPV prevalence was 37.44/100,000 persons. The willingness for participation among women was low concerning the indicators. Their raising should be an emphasized task for public health in favor of reducing mortality from morbidities.
- Published
- 2017
5. [Proposal for the modernization of cervical screening procedure in Hungary].
- Author
-
Koiss R, Boncz I, Hernádi Z, and Szentirmay Z
- Subjects
- Age Factors, Female, Humans, Hungary, Papillomavirus Infections prevention & control, Uterine Cervical Neoplasms diagnosis, Vaginal Smears, Uterine Cervical Dysplasia prevention & control, Early Detection of Cancer methods, Mass Screening organization & administration, Papillomavirus Infections diagnosis, Uterine Cervical Dysplasia diagnosis
- Abstract
Two main considerations played roles in creation of new cervical screening system. One was the proven fact that high-risk human papilloma virus infection plays a role in the development of cervical cancer and pre-cancerous lesions. The other was the implementation of the HPV infection's biological behavior in the new screening strategy. The new screening procedure faithfully reflects the cervical carcinogenesis. An organised, population-based and age differentiated screening method could increase attendance of screening and could decrease the possibility of interval cancer rate due to increased sensitivity. Orv Hetil. 2017; 158(52): 2062-2067.
- Published
- 2017
- Full Text
- View/download PDF
6. The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression.
- Author
-
Varga N, Mózes J, Keegan H, White C, Kelly L, Pilkington L, Benczik M, Zsuzsanna S, Sobel G, Koiss R, Babarczi E, Nyíri M, Kovács L, Attila S, Kaltenecker B, Géresi A, Kocsis A, O'Leary J, Martin CM, and Jeney C
- Subjects
- Adult, Case-Control Studies, Cell Line, Tumor, Colposcopy methods, DNA, Viral genetics, Disease Progression, Early Detection of Cancer methods, Female, HeLa Cells, Humans, Sensitivity and Specificity, Triage methods, Vaginal Smears methods, Uterine Cervical Dysplasia genetics, Uterine Cervical Dysplasia pathology, Biomarkers, Tumor genetics, Papillomaviridae genetics, Papillomavirus Infections pathology, Papillomavirus Infections virology, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms virology
- Abstract
In the era of primary vaccination against HPV and at the beginning of the low prevalence of cervical lesions, introduction of screening methods that can distinguish between low- and high-grade lesions is necessary in order to maintain the positive predictive value of screening. This case-control study included 562 women who attended cervical screening or were referred for colposcopy and 140 disease free controls, confirmed by histology and/or cytology. The cases were stratified by age. Using routine exfoliated liquid based cytological samples RT-PCR measurements of biomarker genes, high-risk HPV testing and liquid based cytology were performed and used to evaluate different testing protocols including sets of genes/tests with different test cut-offs for the diagnostic panels. Three new panels of cellular biomarkers for improved triage of hrHPV positive women (diagnostic panel) and for prognostic assessment of CIN lesions were proposed. The diagnostic panel (PIK3AP1, TP63 and DSG3) has the potential to distinguish cytologically normal hrHPV+ women from hrHPV+ women with CIN2+. The prognostic gene panels (KRT78, MUC5AC, BPIFB1 and CXCL13, TP63, DSG3) have the ability to differentiate hrHPV+ CIN1 and carcinoma cases. The diagnostic triage panel showed good likelihood ratios for all age groups. The panel showed age-unrelated performance and even better diagnostic value under age 30, a unique feature among the established cervical triage tests. The prognostic gene-panels demonstrated good discriminatory power and oncogenic, anti-oncogenic grouping of genes. The study highlights the potential for the gene expression panels to be used for diagnostic triage and lesion prognostics in cervical cancer screening.
- Published
- 2017
- Full Text
- View/download PDF
7. [Assessment of the pilot program for cervical cancer screening by health visitors].
- Author
-
Vajda R, Árváné Egri C, Kovács A, Budai A, Döbrőssy L, Koiss R, Kívés Z, and Boncz I
- Subjects
- Community Health Nursing education, European Union, Female, Humans, Needs Assessment, Pilot Projects, Uterine Cervical Neoplasms psychology, Early Detection of Cancer methods, Health Knowledge, Attitudes, Practice, Uterine Cervical Neoplasms diagnosis
- Abstract
Introduction: Within the tender (6.1.3.A-13/1-2013-0001) supported by the European Union, we wished to involve health visitors into the organized cervical cancer screening program., Aim: The aim of our survey was to assess the satisfaction of health visitors, instructors, and that of the teaching aids. Furthermore, we wished to assess whether the teaching materials met the expectations., Method: Satisfaction of the health visitors was assessed by a survey, in four groups of questions. These involved the assessment of the instructors, the teaching aids, evaluation of the further training day, and the compliance with the knowledge of training. Period for completion of the questionnaires lasted from October to December in 2014. We used descriptive statistics for data evaluation., Results: Data of 2148 health visitors was evaluated. They rated the performance of gynecologist-obstetricians 4.65, that of health visitors 4.61, that of public health professionals 4.56, and that of IT specialists 4.52. 98% of the teaching aids were useful for them and the acquired knowledge was appropriate with their expectations., Conclusion: The health visitors were satisfied with the theoretical instruction within the pilot program. The professionally well prepared health visitors may contribute to the success of the cervical cancer screening program. Orv. Hetil, 2017, 158(12), 461-467.
- Published
- 2017
- Full Text
- View/download PDF
8. Performance of a new HPV and biomarker assay in the management of hrHPV positive women: Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer.
- Author
-
Kocsis A, Takács T, Jeney C, Schaff Z, Koiss R, Járay B, Sobel G, Pap K, Székely I, Ferenci T, Lai HC, Nyíri M, and Benczik M
- Subjects
- Adolescent, Adult, Aged, Biomarkers, Biomarkers, Tumor, Carcinoma, Squamous Cell virology, DNA Methylation, DNA Probes, HPV, DNA, Viral analysis, Female, Homeodomain Proteins genetics, Humans, Hungary epidemiology, Middle Aged, Papillomaviridae isolation & purification, Papillomavirus Infections virology, Precancerous Conditions virology, Promoter Regions, Genetic, Prospective Studies, Real-Time Polymerase Chain Reaction, Reproducibility of Results, Sensitivity and Specificity, Transcription Factor Brn-3C genetics, Triage, Uterine Cervical Dysplasia virology, Uterine Cervical Dysplasia chemistry, Uterine Cervical Neoplasms virology, Young Adult, Carcinoma, Squamous Cell chemistry, Homeodomain Proteins analysis, Papillomavirus Infections metabolism, Precancerous Conditions metabolism, Transcription Factor Brn-3C analysis, Uterine Cervical Dysplasia metabolism, Uterine Cervical Neoplasms chemistry
- Abstract
The ongoing Triage and Risk Assessment of Cervical Precancer by Epigenetic Biomarker (TRACE) prospective, multicenter study aimed to provide a clinical evaluation of the CONFIDENCE™ assay, which comprises a human papillomavirus (HPV) DNA and a human epigenetic biomarker test. Between 2013 and 2015 over 6,000 women aged 18 or older were recruited in Hungary. Liquid-based cytology (LBC), high-risk HPV (hrHPV) DNA detection and single target host gene methylation test of the promoter sequence of the POU4F3 gene by quantitative methylation-specific polymerase chain reaction (PCR) were performed from the same liquid-based cytology sample. The current analysis is focused on the baseline cross-sectional clinical results of 5,384 LBC samples collected from subjects aged 25 years or older. The performance of the CONFIDENCE HPV™ test was found to be comparable to the cobas® HPV test with good agreement. When applying the CONFIDENCE Marker™ test alone in hrHPV positives, it showed significantly higher sensitivity with matching specificity compared to LBC-based triage. For CIN3+ histological endpoint in the age group of 25-65 and 30-65, the methylation test of POU4F3 achieved relative sensitivities of 1.74 (95% CI: 1.25-2.33) and 1.64 (95% CI: 1.08-2.27), respectively, after verification bias adjustment. On the basis of our findings, POU4F3 methylation as a triage test of hrHPV positives appears to be a noteworthy method. We can reasonably assume that its quantitative nature offers the potential for a more objective and discriminative risk assessment tool in the prevention and diagnostics of high-grade cervical intraepithelial neoplasia (CIN) lesions and cervical cancer., (© 2016 UICC.)
- Published
- 2017
- Full Text
- View/download PDF
9. "Gynaecological cancer screening" or "cervical screening?" The case of Hungary.
- Author
-
Döbrőssy L and Koiss R
- Subjects
- Cervix Uteri pathology, Early Detection of Cancer methods, Female, Gynecology standards, Humans, Hungary, Papillomavirus Infections diagnosis, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Dysplasia diagnosis, Genital Neoplasms, Female diagnosis, Mass Screening methods, Vaginal Smears methods
- Abstract
In Hungary, "gynaecological cancer screening" by gynaecologists having interest in oncology has had a long history. The screening tool was colposcopy alone embedded in complete gynaecological examination. Later on smear-taking for cytology has been added. This screening protocol has survived until now both in the gynaecological community and public. In the meantime, as it proved its ef- fectiveness, cytological examination has been internationally recommended,\ as sole method of organized cervical screening; in case of non-negative test result, gynaecological examination including colposcopy is justified. Smear-taking can be undertaken by trained paramedical personnel. The authors have made an attempt to argue the use of "cervical screening" instead of "gynaecological cancer screening", which is deeply entrenched into both professional and public consciousness in Hungary.
- Published
- 2016
10. Claudin-1 as a Biomarker of Cervical Cytology and Histology.
- Author
-
Benczik M, Galamb Á, Koiss R, Kovács A, Járay B, Székely T, Szekerczés T, Schaff Z, Sobel G, and Jeney C
- Subjects
- Case-Control Studies, Colposcopy, Early Detection of Cancer, Female, Follow-Up Studies, Humans, Hungary, Immunoenzyme Techniques, Neoplasm Grading, Neoplasms, Squamous Cell metabolism, Neoplasms, Squamous Cell virology, Papillomaviridae isolation & purification, Papillomavirus Infections metabolism, Papillomavirus Infections virology, Prognosis, Uterine Cervical Neoplasms metabolism, Uterine Cervical Neoplasms virology, Vaginal Smears, Uterine Cervical Dysplasia metabolism, Uterine Cervical Dysplasia virology, Biomarkers, Tumor metabolism, Claudin-1 metabolism, Cytodiagnosis, Neoplasms, Squamous Cell pathology, Papillomavirus Infections pathology, Uterine Cervical Neoplasms pathology, Uterine Cervical Dysplasia pathology
- Abstract
Several immunochemistry tests are used for triaging human papilloma virus (HPV) and cytology positive cases in cervical cancer screening and as an adjunct test to diagnose cervical cancer. Claudin-1 (CLDN1) protein is a major component of the tight junction, shown to have altered expression in cervical cancer. In this study, value of CLDN1 was analysed as a screening and triage immunochemistry test compared to cytology and HPV testing. A population of 352 women attending colposcopic referral visits resulting in cervical conisation and a second population of 150 women attending routine gynaecological visits with negative cervical cytology were enrolled in a multi-centre clinical study in Hungary. Cytology and HPV (Genoid Full Spectrum HPVAmplification and Detection System) testing were carried out along with immunocytochemistry for CLDN1, and as a reference, using CINtec p16 Cytology Kit. Three different evaluation protocols were used which assessed immunostaining characteristics with or without cytological readings. High correlation observable between p16INK4a and CLDN1 established CLDN1 as a competing marker in cervical cancer. Concordance of CLDN1 immunostaining of cervical intraepithelial neoplasia 2 and above (CIN2+) positives was 84.0 % (73.8–89.3); concordance of CIN2+ negatives was 69.0 % (59.6–75.8). In conclusion, CLDN1 has similar diagnostic potential as p16INK4a, our results established it as a histological and cytological biomarker with the potential to improve the clinical performance of cervical cytology and histology.
- Published
- 2016
- Full Text
- View/download PDF
11. Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.
- Author
-
Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, Collas De Souza S, Tjalma WA, Rosenlund M, Fiander A, Castro Sánchez M, Damaskou V, Joura EA, Kirschner B, Koiss R, O'Leary J, Quint W, Reich O, Torné A, Wells M, Rob L, Kolomiets L, Molijn A, Savicheva A, Shipitsyna E, Rosillon D, and Jenkins D
- Subjects
- Adult, Aged, Carcinoma, Adenosquamous virology, Cross-Sectional Studies, Europe epidemiology, Female, Human papillomavirus 16 genetics, Humans, Middle Aged, Papillomavirus Infections virology, Prevalence, Retrospective Studies, Uterine Cervical Neoplasms virology, Young Adult, Uterine Cervical Dysplasia virology, Carcinoma, Adenosquamous epidemiology, Papillomavirus Infections epidemiology, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Dysplasia epidemiology
- Abstract
Cervical glandular neoplasias (CGN) present a challenge for cervical cancer prevention due to their complex histopathology and difficulties in detecting preinvasive stages with current screening practices. Reports of human papillomavirus (HPV) prevalence and type-distribution in CGN vary, providing uncertain evidence to support prophylactic vaccination and HPV screening. This study [108288/108290] assessed HPV prevalence and type-distribution in women diagnosed with cervical adenocarcinoma in situ (AIS, N = 49), adenosquamous carcinoma (ASC, N = 104), and various adenocarcinoma subtypes (ADC, N = 461) from 17 European countries, using centralised pathology review and sensitive HPV testing. The highest HPV-positivity rates were observed in AIS (93.9%), ASC (85.6%), and usual-type ADC (90.4%), with much lower rates in rarer ADC subtypes (clear-cell: 27.6%; serous: 30.4%; endometrioid: 12.9%; gastric-type: 0%). The most common HPV types were restricted to HPV16/18/45, accounting for 98.3% of all HPV-positive ADC. There were variations in HPV prevalence and ADC type-distribution by country. Age at diagnosis differed by ADC subtype, with usual-type diagnosed in younger women (median: 43 years) compared to rarer subtypes (medians between 57 and 66 years). Moreover, HPV-positive ADC cases were younger than HPV-negative ADC. The six years difference in median age for women with AIS compared to those with usual-type ADC suggests that cytological screening for AIS may be suboptimal. Since the great majority of CGN are HPV16/18/45-positive, the incorporation of prophylactic vaccination and HPV testing in cervical cancer screening are important prevention strategies. Our results suggest that special attention should be given to certain rarer ADC subtypes as most appear to be unrelated to HPV., (© 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.)
- Published
- 2015
- Full Text
- View/download PDF
12. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
- Author
-
Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, and Holl K
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Alphapapillomavirus genetics, Alphapapillomavirus isolation & purification, Cervix Uteri pathology, Cervix Uteri virology, Cross-Sectional Studies, DNA, Viral analysis, Europe epidemiology, Female, Humans, Middle Aged, Neoplasm Grading, Uterine Cervical Neoplasms pathology, Young Adult, Uterine Cervical Dysplasia pathology, Alphapapillomavirus classification, Papillomavirus Infections epidemiology, Papillomavirus Infections virology, Uterine Cervical Neoplasms virology, Uterine Cervical Dysplasia virology
- Abstract
Knowledge of differences in human papillomavirus (HPV)-type prevalence between high-grade cervical intraepithelial neoplasia (HG-CIN) and invasive cervical cancer (ICC) is crucial for understanding the natural history of HPV-infected cervical lesions and the potential impact of HPV vaccination on cervical cancer prevention. More than 6,000 women diagnosed with HG-CIN or ICC from 17 European countries were enrolled in two parallel cross-sectional studies (108288/108290). Centralised histopathology review and standardised HPV-DNA typing were applied to formalin-fixed paraffin-embedded cervical specimens dated 2001-2008. The pooled prevalence of individual HPV types was estimated using meta-analytic methods. A total of 3,103 women were diagnosed with HG-CIN and a total of 3,162 with ICC (median ages: 34 and 49 years, respectively), of which 98.5 and 91.8% were HPV-positive, respectively. The most common HPV types in women with HG-CIN were HPV16/33/31 (59.9/10.5/9.0%) and in ICC were HPV16/18/45 (63.3/15.2/5.3%). In squamous cell carcinomas, HPV16/18/33 were most frequent (66.2/10.8/5.3%), and in adenocarcinomas, HPV16/18/45 (54.2/40.4/8.3%). The prevalence of HPV16/18/45 was 1.1/3.5/2.5 times higher in ICC than in HG-CIN. The difference in age at diagnosis between CIN3 and squamous cervical cancer for HPV18 (9 years) was significantly less compared to HPV31/33/'other' (23/20/17 years), and for HPV45 (1 year) than HPV16/31/33/'other' (15/23/20/17 years). In Europe, HPV16 predominates in both HG-CIN and ICC, whereas HPV18/45 are associated with a low median age of ICC. HPV18/45 are more frequent in ICC than HG-CIN and associated with a high median age of HG-CIN, with a narrow age interval between HG-CIN and ICC detection. These findings support the need for primary prevention of HPV16/18/45-related cervical lesions., (Copyright © 2012 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.